



DATE	STOCK	RECOMD	ENTRY PRICE	TARGET	STOP LOSS
3.12.2018	APOLLOTYRE	BUY	239	262	226
3.12.2018	CADILAHC	BUY	363	388	348
3.12.2018	HEIDELBERG	BUY	150	162	143

**NOTE –Stop Loss are on Daily closing basis.**

**TECHNICAL OUTLOOK**

NIFTY WEEKLY CLOSE – 10876.75 (↑ 350 pts)

Last week, Nifty began on a positive note and moved swiftly up to cross the 10800 level and closed the week at 10876 with a gain of 350 points.

During the week, Nifty moved above all key daily and weekly EMAs. Also there is an indication of positive EMA cross-over on daily charts. The daily as well as weekly RSI is above the average.

As mentioned in our earlier report, a strong move above 10800-10850 level has turned the short term trend positive. Going ahead, the 11000-11070 remains a resistance level for Nifty in this pull-back. On the other hand, 10770-10700 would be the immediate support now.





**WEEKLY INVESTMENT IDEAS REVIEW**

DATE	STOCK	RECOMD	ENTRY PRICE	TARGET	STOP LOSS	TODAY CLOSE	NET % CHANGE	REMARK
26.11.2018	CHAMBLFERT	BUY	150	165	142	153.1	2.02	Exit
26.11.2018	OIL	BUY	205	220	195	186.25	-10.07	Stop Loss Hit
26.11.2018	ZEEL	BUY	458	485	442	488.6	6.26	Target Achieved

**WEEKLY MARKET REVIEW**

**Sensex regains 36,000**

A steady decline in crude oil prices and firmness in rupee boosted domestic stocks in the week gone by. Indices logged gains on all five trading sessions during the week. The barometer index, the S&P BSE Sensex, regained the psychological 36,000 level during the week.

In the week ended Friday, 30 November 2018, the Sensex rose 1,213.28 points or 3.47% to settle at 36,194.30. The Nifty 50 index rose 350 points or 3.32% to settle at 10,876.75. The BSE Mid-Cap index rose 159.01 points or 1.07% to settle at 15,039.35. The BSE Small-Cap index rose 76.33 points or 0.53% to settle at 14,427.16.

Yes Bank lost 13.24%. Rating agency ICRA downgraded Yes Bank's domestic long term ratings of Senior Debt Instruments to ICRA AA from ICRA AA +and Subordinate Debt Instruments to ICRA AA- from ICRA AA. The ratings remain on watch with negative implications. CARE Ratings downgraded the bank's domestic ratings of Senior Debt Instruments to CARE AA +from CARE AAA and Subordinate Debt Instruments to CARE AA from CARE AA+. The ratings remain on credit watch with developing implications. The bank's foreign currency issuer ratings were downgraded to Ba1 from Baa3 by Moody's Investors Service. The outlook, where applicable, was changed to negative from stable. At the same time, Moody's has affirmed the bank's counterparty risk assessment (CR Assessment) of Baa3(cr)/ P-3(cr) and domestic and foreign currency counterparty risk rating (CRR) of Baa3/ P-3.

Bharti Airtel fell 4.39%. Airtel Africa, a subsidiary of Bharti Airtel, announced the appointment of global banks for an intended IPO on an international stock exchange. This follows the recent subscription of shares in Airtel Africa by six leading global investors for an aggregate consideration of \$1.25 billion. Airtel Africa is a pan-African telecommunications company with operations in 14 countries across Africa. Its

product offerings include 2G, 3G and 4G wireless voice and data services and mobile commerce through Airtel Money.

Sun Pharmaceutical Industries lost 6.37%. Sun Pharma announced that it entered into a definitive agreement to acquire Pola Pharma Inc. (Pola Pharma), a Japanese pharmaceutical company engaged in research and development, manufacture, sale and distribution of branded and generic products in Japan. The portfolio of Pola Pharma primarily comprises dermatology products. The transaction is expected to close on or before 31 January 2019, subject to completion of closing conditions. In a separate announcement, Sun Pharma and one of its wholly-owned subsidiaries entered into settlements with certain plaintiffs in the In re Modafinil Antitrust Litigation matter pending in the United States District Court for the Eastern District of Pennsylvania. The settlements extend to all claims brought by the Direct Purchaser Plaintiffs. The terms of the settlements are confidential, Sun Pharma said.

In the foreign exchange market, the rupee edged higher against the dollar. The partially convertible rupee was hovering at 69.81, compared with its close of 69.85 during the previous trading session.

In the global commodities markets, Brent for January 2019 settlement was off 51 cents at \$59 a barrel. The contract had risen 75 cents, or 1.28% to settle at \$59.51 a barrel during the previous trading session.

On the political front, Assembly elections in Madhya Pradesh and Mizoram were held on 28 November 2018. Polling in Rajasthan and Telangana will be held on 7 December 2018. The election to the 90-member Chhattisgarh Assembly was held in two phases 12 and 20 November 2018. Counting of votes will be held across all the five states on 11 December 2018.

Source: [www.capitalmarket.com](http://www.capitalmarket.com)



### SAJAG SECURITIES PVT. LTD.

MEMBER: NATIONAL STOCK EXCHANGE OF INDIA LTD.

MEMBER: BOMBAY STOCK EXCHANGE LTD.

DEPOSITORY PARTICIPANT: NATIONAL SECURITIES DEPOSITORY LTD.

DEPOSITORY PARTICIPANT: CENTRAL DEPOSITORY SERVICES LTD.

33/15 - B, KARVE ROAD, REGENT CHAMBERS, PUNE - 411004, TEL: 91-20-66014737, FAX: 91-20-25302555

email : [business@sajag.co.in](mailto:business@sajag.co.in) / [investorgrievance@sajag.co.in](mailto:investorgrievance@sajag.co.in)

NSE TM ID - 07549

BSE TM ID - 3105

NSDL DP ID: IN303647

SEBI Regn. No. INB 230754937

SEBI Regn. No. INB 010754936

CDSL DP ID : 12062400

**Disclosure:** This report is issued by Sajag Securities Pvt. Ltd. (SSPL), a stock broking company, which is regulated by SEBI and its research activities are as per SEBI Guidelines for Research Analysts December 2014. Registration Number: INH000001923. This report is prepared and distributed by SSPL for information purpose only. SSPL and the research analyst(s) who prepared this report do not have any long or short positions in derivatives markets in any of the above mentioned securities. SSPL or the research analyst(s) do not have ownership of 1% or more in the company. The research analyst(s) who prepared this research report hereby certifies that the views expressed in this research report accurately reflect the research analyst's personal views about all of the subject issuers and/or securities, that the analyst(s) have no known material conflict of interest and no part of the research analyst's compensation was, is or will be, directly or indirectly, related to the specific views or recommendations contained in this research report.

**Disclaimer:** Neither the information contained herein nor any opinion expressed should be construed or deemed to be construed as solicitation or as offering advice for the purposes of the purchase or sale of any security or investment or derivatives. The information and opinions contained in the report were considered by SSPL to be valid when published. The report also contains information provided to SSPL by third parties. The source of such information will usually be disclosed in the report. While SSPL has taken all responsible steps to ensure that this information is correct, SSPL does not offer any warranty as to the accuracy or completeness of such information. Any person placing reliance on the report to undertake trading does so entirely at his/her own risk and SSPL does not accept any liability as a result. Securities and Derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily a guide to future performance. The report does not have regard to the specific investment objective, financial situation and the particular needs of any specific person who may receive this report. Investor must undertake independent analysis with their own legal, tax and financial advisors and reach their own decision regarding the appropriateness of investing in any securities or investment strategies discussed and recommended in this report and should understand that statements regarding future prospects may not be realized. In no circumstances be it used or considered as an offer to sell or a solicitation of any offer to buy or sell the securities mentioned in it. The information contained in the research reports may have been taken from trade and statistical services and other sources, which we believe reliable. SSPL does not guarantee that such information is accurate or complete and it should not be relied upon as such. Any opinions expressed reflect judgments at this date and are subject to change without notice. The target prices mentioned in the report are based on certain assumptions as of the date appearing in the material and may be subject to change from time to time without notice.